z-logo
open-access-imgOpen Access
Role for Metallothionein-3 in the Resistance of Human U87 Glioblastoma Cells to Temozolomide
Author(s) -
Rosa Santangelo,
Enrico Rizzarelli,
Agata Copani
Publication year - 2020
Publication title -
acs omega
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.779
H-Index - 40
ISSN - 2470-1343
DOI - 10.1021/acsomega.9b04483
Subject(s) - u87 , temozolomide , apoptosis , glioma , metallothionein , gene silencing , cancer research , cell cycle , cell cycle checkpoint , cell culture , glioblastoma , chemistry , cytotoxic t cell , programmed cell death , cell growth , drug resistance , biology , microbiology and biotechnology , in vitro , biochemistry , gene , genetics
Metallothioneins (MTs) are metal-binding proteins that are overexpressed in various human cancers and are thought to be associated with resistance to cytotoxic drugs. The knowledge on MT expression, regulation, and function in human gliomas is limited. We found that MT3 mRNA was highly expressed in cell lines derived from grade IV gliomas ( i.e ., A172 and U87 cells), as compared to grade II astrocytoma cells ( i.e ., 1321N1). Different from 1321N1, U87 cells were partly resistant to the alkylating drug, temozolomide (TMZ) (100 μM for 96 h), which induced a massive accumulation of U87 into the S and G2 fractions of the cell cycle but not apoptotic death. Silencing of MT3 did not significantly affect U87 cell proliferation and survival, but it delayed G1/S transition and favored the occurrence of apoptosis in TMZ-treated cells. Accordingly, the combination of MT3 silencing and TMZ treatment increased the protein levels of checkpoint kinase-1, which was ultimately responsible for the lasting G1 arrest and death of double treated U87 cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom